Amgen (AMGN) Completes Otezla Buyout, Raises 2019 Guidance
Zacks Investment Research | Nov 21, 2019 09:43PM ET
Amgen Inc. (NASDAQ:AMGN) announced that it has completed the previously-announced acquisition of Celgene’s blockbuster psoriasis drug Otezla, which the latter had to divest in order to complete its merger with Bristol-Myers (NYSE:BMY) .
We remind investors that Amgen agreed to acquire the global commercial rights to Otezla in August.
Amgen had to pay Celgene (NASDAQ:CELG) $13.4 billion in cash or approximately $11.2 billion net of anticipated future cash tax benefits for Otezla and certain related assets and liabilities. Following this buyout, the company raised its overall guidance for 2019.
Amgen now expects total revenues in the range of $23.1-$23.3 billion, previously expected within $22.8-$23.0 billion. Adjusted EPS is expected in the band of $14.5 -$14.7 compared with the previous range of $14.20-14.45.
Otezla is approved to treat psoriasis, psoriatic arthritis and oral ulcers associated with Behçet's disease. The drug recorded sales of $1.4 billion during the first nine months of 2019 and has been one of the key revenue drivers for Celgene. Otezla performed well in the United States on the back of higher demand and internationally, owing to steady expansion in the key markets.
Amgen’s guidance lift is a pure indication that the Otezla purchase is a smart strategic move by the company as it strengthens its existing inflammation franchise portfolio, which includes a blockbuster drug Enbrel. Notably, Pfizer (NYSE:PFE) markets Enbrel outside the United States and Canada.
However, pricing pressure and stiff competition are hurting sales of Enbrel. As a result, Otzela will strengthen Amgen’s portfolio of inflammatory drugs. Amgen expects Otezla to record at least low double-digit sales growth, on average, over the next five years. Notably, Otezla enjoys U.S. patent exclusivity through at least 2028.
Shares of Amgen were up 1% following this news on Thursday. In fact, the stock has rallied 17% so far this year compared with the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.